--- title: "Is Harmonic (HLIT) Quietly Redefining Its Competitive Moat With Brownfield Fiber-Grade Deployments?" type: "News" locale: "en" url: "https://longbridge.com/en/news/287544742.md" description: "Harmonic Inc. is expanding its fiber-grade services in Finland, enhancing multi-gigabit connectivity in challenging brownfield areas. This deployment with DNA Finland highlights Harmonic's role in next-gen broadband, despite concerns over customer concentration and pricing pressures. The company raised its 2026 revenue guidance to $475-$495 million, projecting significant growth through 2029. Analysts have varying views on revenue potential, with some predicting a decline. Investors are encouraged to consider both opportunities and risks in their decision-making." datetime: "2026-05-25T16:28:30.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287544742.md) - [en](https://longbridge.com/en/news/287544742.md) - [zh-HK](https://longbridge.com/zh-HK/news/287544742.md) --- # Is Harmonic (HLIT) Quietly Redefining Its Competitive Moat With Brownfield Fiber-Grade Deployments? - In May 2026, Harmonic Inc. announced that DNA Finland, the country’s second-largest mobile and fixed broadband operator, is expanding multi-gigabit, fiber-grade services into harder-to-serve brownfield apartment buildings using Harmonic’s SeaStar optical node and AI-enabled network intelligence platform. - This move not only broadens DNA Finland’s addressable broadband market but also showcases Harmonic’s ability to unlock multi-gigabit connectivity over existing in-building coax, reducing deployment complexity and costs for large European operators. - We’ll now examine how this expansion of fiber-grade broadband via SeaStar optical nodes could influence Harmonic’s existing investment narrative. AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early. ## Harmonic Investment Narrative Recap To own Harmonic, you need to believe in its role as an enabler of next generation broadband, particularly virtualized and fiber-grade access. The DNA Finland SeaStar deployment reinforces this thesis by highlighting Harmonic’s ability to extend multi-gigabit connectivity using existing coax, but it does not materially change the near term reliance on a concentrated customer base or the risk that technology shifts could erode its product relevance. Among recent announcements, the raised full year 2026 guidance (net revenue of US$475 million to US$495 million and net income of US$40 million to US$50 million) is most relevant. It anchors the current catalyst that strong broadband demand and backlog conversion could support higher earnings, while the DNA Finland win offers incremental evidence that Harmonic’s fiber and AI platforms are gaining traction in new geographies and use cases aligned with that outlook. Yet while this broadband momentum is encouraging, investors should also be aware of how customer concentration and pricing pressure could still... Read the full narrative on Harmonic (it's free!) Harmonic's narrative projects $609.8 million revenue and $92.1 million earnings by 2029. This requires 15.3% yearly revenue growth and about an $83.6 million earnings increase from $8.5 million today. Uncover how Harmonic's forecasts yield a $15.29 fair value, in line with its current price. ## Exploring Other Perspectives HLIT 1-Year Stock Price Chart While the DNA Finland win underscores Harmonic’s broadband potential, the most bearish analysts were assuming revenue could fall to about US$108.4 million by 2029, which shows how differently you and they might weigh customer concentration risk and future orders. Explore 2 other fair value estimates on Harmonic - why the stock might be worth as much as 19% more than the current price! ## The Verdict Is Yours Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. - A great starting point for your Harmonic research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. - Our free Harmonic research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Harmonic's overall financial health at a glance. ## Contemplating Other Strategies? Our daily scans reveal stocks with breakout potential. Don't miss this chance: - Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution. - We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them. - The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### Valuation is complex, but we're here to simplify it. Discover if Harmonic might be undervalued or overvalued with our detailed analysis, featuring **fair value estimates, potential risks, dividends, insider trades, and its financial condition.** Access Free Analysis ### Related Stocks - [HLIT.US](https://longbridge.com/en/quote/HLIT.US.md) ## Related News & Research - [Barclays Keeps Their Hold Rating on Harmonic (HLIT)](https://longbridge.com/en/news/286066606.md) - [Exclusive: The researchers who built AI-generated DNA just raised $50 million to reinvent biology](https://longbridge.com/en/news/289812683.md) - [How New AlloSure Kidney Prognostic Evidence At CareDx (CDNA) Has Changed Its Investment Story](https://longbridge.com/en/news/290274187.md) - [Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress | NTRA Stock News](https://longbridge.com/en/news/290179469.md) - [If You Invested $1000 In United Microelectronics Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/289967210.md)